key: cord-0863156-on1in43c
authors: Zheng, Minyan; Schultz, Michael B.; Sinclair, David A.
title: NAD+ in COVID-19 and Viral Infections
date: 2022-02-11
journal: Trends Immunol
DOI: 10.1016/j.it.2022.02.001
sha: 3b38c0f87a27cd31d94f08bcbb99200a35246b3f
doc_id: 863156
cord_uid: on1in43c

Nicotinamide adenine dinucleotide (NAD+), as an emerging regulator of immune responses during viral infections may be a promising therapeutic target for COVID-19. In this Opinion, we suggest that interventions that boost NAD+ levels might promote antiviral defense and suppress uncontrolled inflammation. We discuss the association between low NAD+ concentrations and risk factors for poor COVID-19 outcomes, including aging and common comorbidities. Mechanistically, we outline how viral infections can further deplete NAD+ and its roles in antiviral defense and inflammation. We also describe how coronaviruses can subvert NAD+-mediated actions via genes that remove NAD+ modifications and activate the NLRP3 inflammasome. Finally, we explore ongoing approaches to boost NAD+ concentrations in the clinic to putatively increase antiviral responses while curtailing hyperinflammation.

A tragic and poorly understood aspect to COVID-19 is the increased susceptibility of the elderly to severe forms of the disease (reviewed in [2] ). Rates of hospitalization, ICU admission, and death increase with age, while the young are often left relatively unscathed [3] . Most infectious diseases afflict both the very old and young, making this demographic pattern for COVID-19 susceptibility, unusual [4] . A better understanding of the mechanisms that render older individuals more susceptible to developing severe disease could lead to new candidate strategies for therapeutic intervention.

We posit that one culprit may be a deficiency in NAD + , the concentrations of which decrease during aging in nearly every tissue studied across species [reviewed in 5] . In rodents, this decrease has been observed in tissues and cells that are relevant to COVID-19 infection, such as the lung, heart, spleen, endothelial cells, and macrophages [6] ; [7] ; [8] ; [9] . A growing body of human data corroborates an association between age and low NAD + concentrations across multiple tissues including the skin, blood, and liver [10];[11];[9]; [12] .

Why NAD + levels fall during aging is an active area of research. Studies in mice have implicated an increase in the concentrations and activity of NAD + -consuming enzymes such as CD38, poly-ADP-ribose polymerase 1(PARP1), and Sterile alpha and TIR motif containing 1(SARM1) [8] ; [13] ; [14] ; [15, 16] , as well as an insufficient flux from NAD + -producing enzymes such as NAD + concentrations are also low in certain comorbidities associated with COVID-19

severity; one such comorbidity is insulin resistance (IR) and diabetes mellitus [20] . Specifically, in mouse models, genetic (KK/HIJ), diet-induced (high-fat diet), and age-associated IR have been associated with lower NAD + concentrations in liver and white adipose tissue, while restoration of NAD + with NAD + boosters such as nicotinamide ribose (NR) and nicotinamide mononucleotide (NMN) (oral or gavage) reverses IR [21] [22] [23] [24] ; [25] . In humans, metabolic syndrome and obesity have been associated with low NAD + concentrations in adipose tissue [26] . Of note, NMN was recently shown to improve insulin sensitivity in prediabetic women, and further clinical studies are ongoing, discussed later in this review [27] (Table 1 ).

In addition, a recently developed oral anti-diabetic medication, imeglimin , can enhance glucosestimulated ATP generation and induce the synthesis of NAD + in pancreatic islets derived from diseased rodents with type 2 diabetes [28] .

Another risk factor for severe COVID-19 is cardiovascular disease (CVD) [29] . Several preclinical studies demonstrate that raising NAD + concentrations in endothelial cells reverses vascular and endothelial dysfunction [30]; [7] . Further studies have shown a beneficial role for NAD + in cardiovascular function in mouse models, including models of dyslipidemia, ischemia-reperfusion injury, and diastolic heart failure [31] (reviewed in [32] [34] , human fibroblasts infected with herpes simplex virus 1 (HSV-1) [35] , and in the skeletal muscle of individuals coinfected with HIV-1 and hepatitis C virus [36] . These effects are presumably due to the induction of NAD + -consuming enzymes such as CD38 and poly(ADP-ribose) polymerases (PARPs) [16] . For instance, CD8 + T lymphocytes expressing CD38 have been proposed as a marker for HIV-1mediated disease progression [43] . The decline of NAD + concentrations in human fibroblasts induced by HSV-1 infection has been associated with increased protein poly(ADP-ribosyl)ation, and can be blocked by pharmacological inhibition of PARP1/PARP2 [35] . relative to mock infection [85] . These observations suggest that NAD + metabolic pathways are under increased demand during SARS-CoV-2 infection, and highlights the potential relevance of NAD + in modulating COVID-19 disease outcomes.

NAD + harbors an important role in fueling the activity of enzymes that regulate mammalian immune responses (reviewed in [41] ; [64] ). Classically, NAD + participates in redox processes, but it also participates in non-redox reactions in which it is hydrolyzed, and it non-enzymatically regulates protein-protein interactions [15] (Figure 1 ). In these latter functions, NAD + acts as a signaling molecule, serving as a marker of energy availability and directing a cell to respond to metabolic changes via the action of NAD + -utilizing enzymes (reviewed in [40] ).

and sirtuins are two NAD + -dependent enzyme families that participate in immune responses (reviewed in [41] ; [64] ). By adding or removing post-translational modifications on key proteins such as NF-κB, they can coordinate the intensity of inflammatory and immune responses (reviewed in [41] ). This places NAD + in an important position for both promoting strong immune responses to pathogens, and for keeping those responses in check.

J o u r n a l P r e -p r o o f Journal Pre-proof PARP1, the preeminent member of the PARP family, is a potent coactivator of the pro-inflammatory transcription factor NF-κB and therefore participates in initiating specific immune responses (reviewed in [41] ). However, this is a double-edged sword, as PARP1 may also increase the severity of cytokine storms as it regulates the expression of many NF-κB-dependent cytokines and chemokines (reviewed in [41] ). Indeed, inhibiting or deleting PARP1 has ameliorated the severity of symptoms in several inflammatory disease rodent models including asthma and colitis [44, 45] ; [46] [47] [48] [49] [50] . For example, PARP1 inhibition (pharmacological or genetic) has prevented ovalbumin-induced lung inflammation in mice [44] and in a guinea pig model of asthma [45] . Treatment with PARP inhibitors has attenuated inflammation associated with colitis seen in IL-10 deficient (Il10 -/-) mice [46] , as well as in trinitrobenzene sulfonic acid-treated rats [48] . Furthermore, PARP1 knockout (KO) (Parp1 -/-) mice are protected from dextran-sulfate sodium-induced colitis compared with wildtype mice [47] . which may indicate a common use of this pathway among viruses. However, the functional consequences of such ADP-ribosylation remain to be investigated [56] . We argue that since PARP enzymatic activity requires NAD + [40] , maintaining a sufficient NAD + concentration may be crucial for achieving PARP-related antiviral mechanisms.

Sirtuins also play a role in antiviral defenses [57] [58] [59] [60] [61] ;(reviewed in [64] ). Indeed, Sirtuin1 (SIRT1) knockout or inhibition promotes the lifecycle and replication of vesicular stomatitis virus (VSV) in mouse embryonic fibroblasts (MEFs) and Kaposi's sarcoma-associated herpesvirus in human lymphoma cell lines [58] ; [59] . Disruption of SIRT1 also increases HPV16 E1-E2

replication [57] . Moreover, knockdown via siRNA of each of the seven sirtuins in human fibroblast cells promoted the growth of a diverse set of human viruses after infection, including human cytomegalovirus (CMV), HSV1, adenovirus type 5 (Ad5), and influenza virus (H1N1) [60] . Furthermore , SIRT1-activating drugs such as resveratrol and CAY10602 have inhibited the replication of these viruses [60] . Another sirtuin , SIRT6, promotes tumor necrosis factor (TNF)α secretion, as evidenced from the suppression of TNFα release from SIRT6 KO MEFs, whereby TNFα secretion would be expected to promote the eradication of pathogens [61] . Indeed, pharmacological inhibition and siRNA knockdown of SIRT6 and NAMPT, an NAD + -synthetic enzyme (Figure 1 ), in mouse fibroblasts promoted CMV replication [62] .

Other NAD + -utilizing enzymes that also play roles during immune responses include CD38 [63] , BST1 [39] , and SARM1 [64] . Indeed, CD38 and BST1 are highly expressed on the J o u r n a l P r e -p r o o f 13, 14, and 15 localize to SGs in human cells, presumably to execute this modification [70] .

As a counter mechanism to the host, many viruses, including coronavirus and alphavirus, deploy ADP-ribosylhydrolases to remove SG-promoting ADP-ribose modifications [73] [74] [75] [76] [77] . SARS-CoV-2 has such a domain with mono-ADP-ribosylhydrolase activity in its largest encoded protein, NSP3 (non-structural protein 3) [80] ; [81] .

Ectopic expression of the SARS-CoV-2 NSP3 macrodomain reverses PARP9-dependent ADP-ribosylation of target proteins [83] . [84, 85] . These findings are relevant as they suggest that the J o u r n a l P r e -p r o o f SARS-CoV-2 NSP3 protein might also interfere with SG formation and thereby allow for evasion of cellular antiviral responses ( Figure 2 ). We argue that providing more NAD + to fuel the activity of PARPs might shift the antiviral balance back in favor of host cells.

One of the potential catastrophic effects of SARS-CoV-2 infections are cytokine storms .

Indeed, the concentrations of circulating pro-inflammatory factors such as IL-1, IL-6, and TNFα are strongly associated with ICU admission and mortality in COVID-19 patients [86] ; [87] ;. Studies of the first SARS pandemic coronavirus, SARS-CoV, have shown that viral proteins play an active role in the processing and release of the two specific pro-inflammatory cytokines, IL-1β and IL-18, by enhancing NF-κB transcriptional activity and promoting the formation of the NLRP3 inflammasome ( Figure 2 ) [82] ; [88] [89] [90] [91] [92] .

The SARS-CoV proteins that facilitate these processes include ORF3a, envelope protein (E), and ORF8b [82] ; [88] [89] [90] [91] [92] . ORF3a mediates NF-κB activation through TRAF3 -dependent ubiquitination of an NF-κB inhibitory subunit, and mediates speck formation of the inflammasome subunit ASC , which accompanies assembly of the NLRP3 inflammasome in human cells [88] .

Additionally, ORF3a has transmembrane domains and ion channel (IC) activity that drives K + efflux, which further promotes activation of the NLRP3 inflammasome . Indeed, IL-1β secretion was completely blocked when BMDMs, stimulated with lentiviruses expressing the SARS-CoV ORF3a, were treated with K + -rich medium [77] ; [82] . The SARS-CoV E protein also promotes inflammasome activation through its intracellular activity ; it forms lipid-protein channels at the ER(endoplasmic reticulum)-Golgi intermediate compartment, and the resulting Ca 2+ stimulates the J o u r n a l P r e -p r o o f activation of the NLRP3 inflammasome. The E protein has also promoted IL-1β release in mammalian cells expressing the NLRP3 inflammasome, while an E protein mutant lacking intracellular activity could not properly secrete IL-1β. [89] ; [90] . ORF8b causes inflammasome activation in human macrophages and interacts directly with NLRP3 in vitro; moreover, it can form protein aggregates and trigger ER stress and lysosomal damage that activate the inflammasome in HeLa cells [91] .

These processes not only promote virulence but may also facilitate viral replication [89, 92] .For example, a comparative study of the functional motifs included within the SARS-CoV viroporins showed that full-length E and ORF3a proteins were required for maximal SARS-CoV replication and virulence in infected mice [89] .

As with SARS-CoV, the SARS-CoV-2 virus can also activate the inflammasome [93] ;

indeed, active NLRP3 inflammasomes have been found in peripheral blood mononuclear cells [99] . SIRT3 mediates inflammasome activation by suppressing mitochondrial ROS (reactive oxygen species) production, which can activate the inflammasome; in this study, siRNA depletion of SIRT3 in human macrophages resulted in increased ROS production and inflammasome activation compared to controls [100] . SIRT6 also promoted the resolution of inflammation via histone H3 lysine 9 (H3K9) deacetylation in the promoters of NF-κ B target genes [97] . However, the effects of sirtuins on the NLRP3 inflammasome have yet to be extensively studied in the context of viral infection.

Along these lines, we posit that NAD + boosters that suppress NF-κB and NLRP3 inflammasome activity might also represent potential treatments to ameliorate the inflammatory symptoms of COVID-19. Indeed, treatment with NR, an NAD + precursor, for 24 hours has been reported J o u r n a l P r e -p r o o f to decrease the release of IL-1β and blunt inflammasome activation in PBMCs from healthy and fasted individuals [100] . NR has also promoted SIRT1 expression, suppressed NLRP3 expression, and reduced the secretion of proinflammatory factors TNFα and IL-6 in mouse hepatocytes [101] . Another NAD + precursor, nicotinic acid (NA), has also reduced inflammation in a rodent model of type 2 diabetes (KK/HIJ mice) by modulating NLRP3 activity [25] . However, consideration should be given to the fact that some studies show that extracellular nucleotides such as NAD + can also promote inflammation via the activation of P2X7 receptors in mouse macrophages and T cells [102 ] .

Given that low NAD + concentrations might exacerbate COVID-19 severity, boosting the levels of this metabolite in at-risk populations is one potential therapeutic strategy for mitigating severe disease . The most straightforward way to raise NAD + concentrations is to provide additional precursors to boost NAD + synthesis (reviewed in [39] ). Canonically, NAD + cannot be taken up directly by the cell, but its precursors can [42] . The NAD + precursors NA, NR , and NMN, all have putative transporters, high safety thresholds, and are orally bioavailable (reviewed in [39] ). They do, however, vary in their pharmacokinetic profiles and seem to raise NAD + concentrations to different extents [113] , although this remains an area of active investigation.

Structurally, the closest molecule to NAD + is NMN, requiring only one enzymatic step to be converted to NAD + . In a double blind, placebo controlled trial, NMN was shown to increase insulin sensitivity in pre-diabetic women [27] (NCT03151239 i ). It is currently being studied in hospitalized COVID-19 patients with hypertension and metabolic syndrome for its effects on fatigue, duration of hospitalization, and viral load (NCT05175768 ii ).

Ongoing clinical trials with NMN are also investigating its effect on hypertension and post-exercise muscle recovery (NCT04903210 iii , NCT04664361 iv ) ( Table 1) .

NR, which is two enzymatic steps removed from NAD + , is also being studied clinically. 

Another approach to raising NAD + concentrations in humans is to inhibit the activity of NAD + -consuming enzymes. For instance, as PARP1 is a major consumer of NAD + in the cell J o u r n a l P r e -p r o o f [41] , PARP1 inhibitors such as olaparib have been extensively studied for the treatment of breast and ovarian cancer, given that PARP1 is synthetically lethal with BRCA mutations [112] .

Regarding COVID-19 infection, one PARP1 inhibitor, CVL218, was recently shown to limit SARS-CoV-2 replication and pro-inflammatory cytokine production in human PBMCs [107] .

Several inhibitors of other NAD + -consuming enzymes are in preclinical development, including against CD38 [108] ; [109] , SARM1 [110] , and ACMSD (which consumes a precursor of NAD + in the kyneurinine pathway) [19] . In humans, treatment with luteolin, a naturally occurring CD38 inhibitor, reduced serum TNF and IL-6 concentrations [111] .

The activation of NAD + biosynthetic enzymes is another strategy to raise NAD + concentrations; a small molecule NAMPT activator, SBI-797812, is currently in preclinical development for cardiovascular and metabolic disease [106 ] . Finally, a virally-encoded protein is a potential target that interferes with NAD + metabolism: the macrodomain of NSP3 can antagonize the antiviral activities of host PARPs, although this remains to be investigated for SARS-CoV2 [81] ; [83] [84] [85] . A few inhibitors of NSP3 were recently

identified in a chemical screen and were shown to exhibit antiviral properties against Chikungunya virus in human epithelial cells [103 ] .

As NAD + metabolism appears to be linked to which stimulates the activation of NLRP3 inflammasome [89] ; [90] . ORF8b is also found to directly J o u r n a l P r e -p r o o f interact with NLRP3 and activate the inflammasome [91] . ACE-2, angiotensin-converting enzyme 2;

Ub, ubiquitination; Ac, acetylation; Casp-1, caspase-1. Created with BioRender.com. • Compared with healthy individuals, NAD + concentrations in tissues and organs are lower in older individuals and in patients with diseases associated with severe COVID-19 symptoms, including diabetes and cardiovascular disease,.

• Viral infections, including coronavirus infections, have been reported to further deplete cellular NAD + stores .

• Many NAD + -dependent enzymes, including members of the sirtuin and poly-ADP-ribose polymerase (PARP) families, display potent antiviral activities.

• SARS-CoV-2 and a variety of viruses possess ADP-ribosylhydrolase enzymatic activity which counteracts the activity of PARPs.

• Viruses such as SARS-CoV-2 can hyperactivate the immune system by activating NF-kB and the NLRP3 inflammasome, potentially leading to deadly cytokine storms. NAD + -boosting compounds may counteract these processes.

• Several NAD + boosting compounds and molecules that target NAD + -producing or consuming enzymes are in clinical development as putative anti-inflammatory or antiviral drugs.

J o u r n a l P r e -p r o o f

COVID-19: combining antiviral and anti-inflammatory treatments

Why Does COVID-19 Disproportionately Affect the Elderly?

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Observations on mortality during the 1918 influenza pandemic

NAD+ in aging: molecular mechanisms and translational implications

Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats

Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of

CD38 Dictates Age-Related NAD Decline and Mitochondrial

Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing

The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration

PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation

A conserved NAD+ binding pocket that regulates protein-protein interactions during aging

Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages

Effects of Kynurenine Pathway Inhibition on NAD Metabolism and Cell Viability in Human Primary Astrocytes and Neurons

Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle

De novo NAD + synthesis enhances mitochondrial function and improves health

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice

Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice

Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice

Nicotinamide riboside ameliorates hepatic metaflammation by modulating NLRP3 inflammasome in a rodent model of type 2 diabetes

Obesity Is Associated With Low NAD(+)/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity

Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice

NAD+ repletion reverses heart failure with preserved ejection fraction

Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular diseases

Vascular endothelial function and oxidative stress are related to dietary niacin intake among healthy middle-aged and older adults

HIV infection decreases intracellular nicotinamide adenine dinucleotide

Herpes simplex virus 1 infection activates poly(ADP-ribose) polymerase and triggers the degradation of poly(ADP-ribose) glycohydrolase

Reduced Levels of NAD in Skeletal Muscle and Increased Physiologic Frailty Are Associated With Viral Coinfection in Asymptomatic Middle-Aged Adults

Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications

Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity

Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

NAD + in aging, metabolism, and neurodegeneration

Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions

Slc12a8 is a nicotinamide mononucleotide transporter

Effect of Withania somnifer on CD38 expression on CD8+ T lymphocytes among patients of HIV infection

Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma

Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs

Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis

Transcriptional Reprogramming and Resistance to Colonic Mucosal Injury in Poly(ADP-ribose) Polymerase 1 (PARP1)-deficient Mice

Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis

Absence of poly(ADP-ribose) polymerase 1 delays the onset of Salmonella enterica serovar Typhimurium-induced gut inflammation

Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation

New PARP gene with an anti-alphavirus function

The Broad-Spectrum Antiviral Protein ZAP Restricts Human Retrotransposition

Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation

Inhibition of filovirus replication by the zinc finger antiviral protein

Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein

The coronavirus nucleocapsid protein is ADP-ribosylated

The deacetylase SIRT1 regulates the replication properties of human papillomavirus 16 E1 and E2

SIRT1 stabilizes PML promoting its sumoylation

Activation of Kaposi's sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle

Sirtuins are evolutionarily conserved viral restriction factors

SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine

Metabolic regulators nampt and sirt6 serially participate in the macrophage interferon antiviral cascade

CD38 in the age of COVID-19: a medical perspective

NAD+-consuming enzymes in immune defense against viral infection

and mRNA decay, with concomitant formation of stress granules and processing bodies

Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm

A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation

Liquid demixing of intrinsically disordered proteins is seeded by poly(ADPribose)

Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3

Stress granule formation, disassembly, and composition are regulated by alphavirus ADP-ribosylhydrolase activity

ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3 macrodomain are critical for initiation of virus replication

The Viral Macrodomain Counters Host Antiviral ADP-Ribosylation

The YXXΦ motif within the severe acute respiratory syndrome coronavirus (SARS-CoV) 3a protein is crucial for its intracellular transport

Inflammasome Activation and ROS Production in Trophoblasts

Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication

Molecular Basis for ADP-Ribose Binding to the Mac1 Domain of SARS-CoV-2 nsp3

The SARS-CoV-2 Conserved Macrodomain Is a

Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome

The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signaling

The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection

The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis

Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome

SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes

Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway

SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase

SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaBdependent gene expression and organismal life span

Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells

An Acetylation Switch of the NLRP3 Inflammasome Regulates Aging-Associated Chronic Inflammation and Insulin Resistance

Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects

Nicotinamide riboside regulates inflammation and mitochondrial markers in AML12 hepatocytes

Differential regulation of P2X7 receptor activation by extracellular nicotinamide adenine dinucleotide and ecto-ADP-ribosyltransferases in murine macrophages and T cells

Is the ADP ribose site of the Chikungunya virus NSP3 Macro domain a target for antiviral approaches?

Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Boosting NAD+ with a small molecule that activates NAMPT

An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Discovery, synthesis, and biological evaluation of thiazoloquin(az)olin(on)es as potent CD38 inhibitors

A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline

Identification of the first noncompetitive SARM1 inhibitors

Children with autism spectrum disorders, who improved with a luteolincontaining dietary formulation, show reduced serum levels of TNF and IL-6

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1067-are NAD + tissue levels reduced during aging? Many hypotheses exist to date

• Are low NAD + concentrations associated with severe COVID-19? There is little data to date showing a direct association

• Can raising NAD + tissue concentrations reduce COVID-19 symptoms, severity, and mortality in the elderly and in the young?

• Can NAD + boosters reduce COVID-19 severity after the onset of symptoms, or only prophylactically?

NR, activators of NAD + biosynthesis, or inhibitors of enzymes that consume NAD + ? • What role does NAD + play in promoting stress granule-dependent antiviral mechanisms? • How does SARS-CoV-2 modulate NAD + and NSP3 to increase virulence